Spain's Senate Passes Motion Urging Government to Develop Specific E-Cigarette Regulations

Nov.28.2024
Spain's Senate Passes Motion Urging Government to Develop Specific E-Cigarette Regulations
The Spanish Senate has passed a motion urging the government to enhance e-cigarette regulation, calling for restrictions on sales channels and flavors, as well as conducting scientific assessments to analyze the impact of new tobacco products.

According to Diario Siglo XXI's report on November 27th, the Health Committee of the Spanish Senate passed a motion on Wednesday (27th) urging the government to strengthen political consensus on smoking control issues and to develop specific regulations for e-cigarettes.


The motion was proposed by the People's Party (PP) and accepted with amendments from the Spanish Socialist Workers' Party (PSOE). The motion passed with 26 votes in favor, 0 votes against, and 2 abstentions. Senator Rosa Romero from the People's Party emphasized that the government must reach a political consensus on smoking policies within the National Health System's interregional committee, ensuring that all autonomous communities are involved in relevant decision-making.


Romero pointed out that the National Smoking Prevention and Control Plan approved by the ministerial meeting on April 30 this year did not take into account the opinions of the autonomous regions, but was merely presented as an information sharing form at the plenary meeting.


The motion also calls for specific regulations on e-cigarettes, restricting the sale of these products to licensed tobacco shops and specialty retailers only. It also prohibits the use of flavors and designs in products and advertisements that appeal to minors in order to reduce underage exposure to e-cigarettes. Additionally, it demands specific regulations on the distribution of nicotine pouches or other nicotine delivery formats that are not classified as smoking cessation medications.


In the initial motion text, the People's Party urges the government to immediately initiate a multi-center scientific assessment supported by public resources to obtain sufficient data to analyze the impact of new tobacco products.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

From myblu to Zone: Imperial Brands Refocuses NGP Strategy in HY26
From myblu to Zone: Imperial Brands Refocuses NGP Strategy in HY26
mperial Brands’ HY26 results point to a more selective NGP transition. The company is using cash flow from traditional tobacco to fund targeted investments in modern oral nicotine, heated tobacco and reusable vaping systems. Its decision to exit the legacy myblu vaping business in the U.S., while expanding Zone nicotine pouches. In Europe, Imperial’s NGP growth is being driven by a multi-category portfolio including blu, Pulze and Zone/Skruf.
Special Report
May.12
Altria Reports Q1 2026 Net Revenues of $5.43 Billion and 7.3% Growth in Adjusted Diluted EPS
Altria Reports Q1 2026 Net Revenues of $5.43 Billion and 7.3% Growth in Adjusted Diluted EPS
Altria Group reported its first-quarter 2026 results on April 30. Net revenues were $5.43 billion, up 3.2% year on year, while revenues net of excise taxes were $4.76 billion, up 5.3%. Reported diluted EPS was $1.30, up more than 100%, and adjusted diluted EPS was $1.32, up 7.3%.
May.06 by 2FIRSTS.ai
    Shenzhen Tobacco Monopoly Bureau Moves to Advance E-Cigarette Regulatory System 2.0
Shenzhen Tobacco Monopoly Bureau Moves to Advance E-Cigarette Regulatory System 2.0
The Shenzhen Tobacco Monopoly Bureau recently held the city’s 2026 e-cigarette regulation work conference to implement higher-level meeting requirements, review the city’s e-cigarette regulatory work in 2025 and during the 14th Five-Year Plan period, assess the current situation, and deploy the rollout of E-cigarette Regulatory System 2.0 across Shenzhen’s tobacco commercial system.
Apr.28 by 2FIRSTS.ai
BofA: U.S. Nicotine Market Splits as Vapor Sales Fall 17.2% and Oral Tobacco Rises 5.8%
BofA: U.S. Nicotine Market Splits as Vapor Sales Fall 17.2% and Oral Tobacco Rises 5.8%
According to Investing.com citing Bank of America scanner data for the four weeks ending May 30, U.S. nicotine category performance was mixed, with cigarette, vapor and cigar sales declining while oral tobacco sales rose 5.8%.
Jun.10
PMI’s Smoke-Free Business Accounts for 43% of Net Revenues in Q1 as Full-Year EPS Guidance Rises
PMI’s Smoke-Free Business Accounts for 43% of Net Revenues in Q1 as Full-Year EPS Guidance Rises
On April 22, 2026, Philip Morris International released its first-quarter 2026 results. The report showed net revenues of $10.146 billion, up 9.1% year on year; adjusted diluted EPS of $1.96, up 16.0%; and smoke-free products accounting for 43% of total net revenues. Based on first-quarter performance, the company raised its 2026 full-year adjusted diluted EPS forecast to $8.36 to $8.51, or $8.11 to $8.26 excluding currency.
Apr.23 by 2FIRSTS.ai
FDA Tobacco Center Plans Faster Review Process for Certain Supplemental PMTAs
FDA Tobacco Center Plans Faster Review Process for Certain Supplemental PMTAs
FDA Center for Tobacco Products Acting Director Bret Koplow issued a statement on May 7 outlining new steps to accelerate tobacco product premarket application review. The statement said CTP reduced the backlog of applications by approximately 70% in 2025 and that there is no longer a queue for PMTAs pending acceptance review.
May.09 by 2FIRSTS.ai